Report Overview

The global neurologic disorders therapeutics market size stood at around USD XX billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 5% during the forecast period.

The advances in the diagnosis of neurodegenerative indications will be one of the critical neurological disorders therapeutics market trends. The early diagnosis of neurodegenerative indications is difficult because of their complex nature, fast progression, and lack of effective diagnostic processes. This has encouraged researchers to focus on the development of novel biomarkers that can accurately detect neurodegenerative indications.



Market Drivers

The neurological disorders therapeutics market analysis highlights the approval of novel drugs as another key factor that will drive market growth during the forecast period. For instance, the approval of OCREVEUS, a CD20 antigen inhibitor developed by Roche has boosted the adoption of therapeutics for the treatment of multiple sclerosis. The high demand for OCREVEUS for the treatment of multiple sclerosis can be attributed to the disease-modifying nature of the drug. Similarly, several other drugs received approval for the treatment of various neurologic indications, such as schizophrenia, bipolar disorder, depression, ADHD, and OCD. This rising number of drug approvals will fuel the demand for neurological disorders therapeutics, consequently driving the growth of the market at a CAGR of almost 5% during the forecast period.

Increasing neurologic disorder prevalence also drives the market growth.

Major Neurologic Disorders

The major disorders include epilepsy, Alzheimers disease, Parkinsons disease, multiple sclerosis, cerebrovascular diseases, and others.